How long to take dostarlimab for mismatch repair deficient rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests how long treatment with a drug called dostarlimab (an immunotherapy that helps your immune system fight cancer) should continue in people with a certain type of rectal cancer. The goal is to see if treatment can be shortened based on how well the tumor responds, which may mean fewer side effects and a quicker recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage II or III rectal cancer that has not spread to distant organs.
- Your tumor must have a specific marker called dMMR or MSI-H (your doctor can check this).
- You should be in good enough health to carry on your daily activities (ECOG score 0 or 1).
- You must NOT have had prior radiation, chemotherapy, or surgery for this rectal cancer.
- You must not have an active autoimmune disease that needed treatment in the last two years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach: giving the immunotherapy drug dostarlimab along with a short course of radiation before surgery, with the goal of avoiding surgery in many patients. It is for people with a specific type of rectal cancer (MSI-H or dMMR) that has not spread to other organs.
This Phase 2 trial studies dostarlimab (an immune therapy that targets PD-1) given before surgery or other initial treatment. It aims to shrink certain locally advanced cancers that have mismatch repair deficiency, potentially making treatment easier and improving outcomes.
This study tests dostarlimab given before surgery for stage II or III colon cancer that has a specific DNA repair defect. It aims to shrink or control the cancer so that some people may be able to skip surgery if the results are good.
This study looks at how well the immunotherapy drug dostarlimab works before surgery in patients with a specific type of advanced rectal cancer that has DNA repair problems (called dMMR/MSI-H). The goal is to see if it is safe and effective in the real world.
This trial studies dostarlimab given around the time of colon cancer surgery for people with untreated, resectable (operable) stage T4N0 or stage III colon cancer that has specific tumor markers. It may help shrink or eliminate the cancer before or after surgery by boosting the immune response.
This trial tests a drug called dostarlimab for people with certain advanced cancers that have a specific genetic feature (dMMR/MSI-H). The goal is to see if it helps shrink or control the cancer in people who haven't had other treatments yet.
Hear when a new Neoplasms, Rectal trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.